Share

|

|

|

Mycophenolate mofetil withdrawal feasible in SLE patients with stable disease

Patients with systemic lupus erythematosus may be able to stop taking mycophenolate mofetil once their condition becomes stable without significantly increasing their risk for flare compared with continuing treatment, suggests an open-label, randomized controlled trial.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Blood immunoassay shows high diagnostic accuracy for Alzheimer’s disease pathology

Elderly woman in hospital room with doctor and nurse. Neurologist holding anatomical model of human brain, conceptual image

A commercially available plasma phosphorylated (p)-tau217 immunoassay outperforms other biomarkers in accurately identifying biological Alzheimer’s disease, suggest findings from a study across three observational cohorts.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Add-on telitacicept improves clinical response in patients with active SLE

Telitacicept used in addition to standard therapy shows promising efficacy in Chinese patients with active systemic lupus erythematosus, suggests a phase 2b trial published in the Annals of the Rheumatic Diseases.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Cerliponase alfa treatment shows extended efficacy for CLN2 disease

Cerliponase alfa treatment slows the progression of neuronal ceroid lipofuscinosis type 2 disease for at least 5 years, shows an open-label extension study in The Lancet Neurology.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

VTE rates not significantly reduced by apixaban in paediatric ALL or lymphoma

Apixaban does not significantly reduce the rate of venous thromboembolism relative to standard care in paediatric patients with acute lymphoblastic leukaemia or lymphoma, show data from the phase 3 PREVAPIX-ALL trial.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Respiratory infection risk heightened in primary Sjögren’s syndrome and ILD

Patients with primary Sjögren’s syndrome and interstitial lung disease are at increased risk of respiratory infections, particularly bacterial infections, suggests a study published in Clinical Rheumatology.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.